Cablivi, a treatment for aTTP, has its price shaped by multiple elements. High R&D costs play a role, as years of research and testing are involved in creating this unique therapy. The complex production process also contributes, with specific techniques required to manufacture the drug accurately.
Market factors matter too. Since aTTP is a rare disease, the limited patient pool restricts large - scale production, keeping prices high. Additionally, competition from alternative treatments can influence Cablivi's price positioning in the market.

